JP7672641B2 - 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット - Google Patents

移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット Download PDF

Info

Publication number
JP7672641B2
JP7672641B2 JP2022517823A JP2022517823A JP7672641B2 JP 7672641 B2 JP7672641 B2 JP 7672641B2 JP 2022517823 A JP2022517823 A JP 2022517823A JP 2022517823 A JP2022517823 A JP 2022517823A JP 7672641 B2 JP7672641 B2 JP 7672641B2
Authority
JP
Japan
Prior art keywords
alberestat
subject
pharma
gvhd
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500182A (ja
JP2023500182A5 (https=
Inventor
パーキン，ジャクリーン
サン，アンソニー
ゼット． パブレティク，スティーブン
イム，アニー
ジー． ホルツマン，ノア
ジェイ． ピア，コーディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2023500182A publication Critical patent/JP2023500182A/ja
Publication of JP2023500182A5 publication Critical patent/JP2023500182A5/ja
Application granted granted Critical
Publication of JP7672641B2 publication Critical patent/JP7672641B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022517823A 2019-09-17 2020-09-17 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット Active JP7672641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901638P 2019-09-17 2019-09-17
US62/901,638 2019-09-17
PCT/EP2020/075948 WO2021053058A1 (en) 2019-09-17 2020-09-17 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease

Publications (3)

Publication Number Publication Date
JP2023500182A JP2023500182A (ja) 2023-01-05
JP2023500182A5 JP2023500182A5 (https=) 2023-09-28
JP7672641B2 true JP7672641B2 (ja) 2025-05-08

Family

ID=72560598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517823A Active JP7672641B2 (ja) 2019-09-17 2020-09-17 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット

Country Status (10)

Country Link
US (1) US20220354833A1 (https=)
EP (1) EP4031138A1 (https=)
JP (1) JP7672641B2 (https=)
KR (1) KR20220079527A (https=)
CN (1) CN114650819A (https=)
AU (1) AU2020349353A1 (https=)
BR (1) BR112022004861A2 (https=)
CA (1) CA3154761A1 (https=)
IL (1) IL290991A (https=)
WO (1) WO2021053058A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
US12411144B2 (en) 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
IL297211B2 (en) * 2020-04-16 2025-12-01 Mereo Biopharma 4 Ltd Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제
WO2023212288A1 (en) * 2022-04-28 2023-11-02 Children's Hospital Medical Center Methods for improving outcomes for hematopoietic cell transplant recipients at risk for bronchiolitis obliterans syndrome
GB202319953D0 (en) * 2023-12-22 2024-02-07 Mereo Biopharma 4 Ltd Tablet formulations involving alvelestat

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518623A (ja) 2009-02-20 2012-08-16 アストラゼネカ・アクチエボラーグ Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩
JP2015517469A (ja) 2012-05-01 2015-06-22 デユーク・ユニバーシテイ 移植片拒絶のバイオマーカーとしてのヘパラン硫酸の組成物および方法
JP2017522350A (ja) 2014-07-31 2017-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
AU1581692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
DE69229552T2 (de) 1991-05-23 1999-12-23 Merrell Pharmaceuticals Inc., Cincinnati Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
EP0636144A1 (en) 1992-04-16 1995-02-01 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
US5486529A (en) 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
DE69314169T2 (de) 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
NZ284766A (en) 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
EP0804465B1 (en) 1994-06-02 2003-08-06 Aventis Pharmaceuticals Inc. Novel elastase inhibitors
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
GB9502152D0 (en) 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
CA2250209A1 (en) 1996-03-28 1997-10-09 Glaxo Group Limited Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
EP0850252B1 (en) 1996-04-12 2005-06-08 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
WO2000032216A1 (en) 1998-06-03 2000-06-08 Cortech Inc. Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
KR20010078724A (ko) 1998-06-03 2001-08-21 존 더블류. 갈루치 2세 세린 프로테아제 저해제로서의 인돌 및테트라히드로이소퀴놀린을 함유하는 α-케토 옥사디아졸
US20030069187A1 (en) 2001-10-05 2003-04-10 Rao Srinivasa K. Elastase inhibitors
US20030119073A1 (en) 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP4825194B2 (ja) 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
ES2428503T3 (es) 2004-02-26 2013-11-08 Bayer Intellectual Property Gmbh 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
WO2006070012A1 (en) 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
WO2009013444A1 (en) 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
DE602007009095D1 (de) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
JP5270538B2 (ja) 2006-05-23 2013-08-21 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
CA2651762A1 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2293832B1 (es) 2006-07-17 2009-05-04 Cargoflet S.A. Sistema de transporte masivo de gas natural a alta presion por via maritima.
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
AU2008214217B2 (en) 2007-02-09 2011-10-13 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009037413A1 (en) 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2217591A4 (en) 2007-11-06 2011-10-26 Astrazeneca Ab CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS
WO2009060206A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
GB0817429D0 (en) 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
AU2010302420B2 (en) 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
US20110212181A1 (en) 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
CA2848557A1 (en) 2011-09-14 2013-03-21 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
WO2013084199A1 (en) 2011-12-07 2013-06-13 Universidade De Lisboa Boron heterocycles as new inhibitors of human neutrophil elastase
CA2878792A1 (en) 2012-07-12 2014-01-16 Chiesi Farmaceutici S.P.A. Inhibition of enzymes
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN105873933A (zh) 2013-12-16 2016-08-17 奇斯药制品公司 作为人中性白细胞弹性蛋白酶抑制剂的四氢三唑并嘧啶衍生物
DK3087094T3 (da) 2013-12-27 2022-08-29 Polyphor Ag Betahårnål peptidomimetika som selektive elastase inhibitorer
JP6499182B2 (ja) 2013-12-27 2019-04-10 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ 選択的エラスターゼ阻害剤としてのβ−ヘアピンペプチド模倣体
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016020070A1 (en) 2014-08-05 2016-02-11 Gerard Voerman Mutants of leech derived neutrophil elastase inhibitors and uses thereof
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
US9890169B2 (en) 2015-12-14 2018-02-13 Chiesi Farmaceutici S.P.A. Triazolinone compounds as HNE inhibitors
WO2017207430A1 (en) 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Imidazolone compounds as human neutrophil elastase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518623A (ja) 2009-02-20 2012-08-16 アストラゼネカ・アクチエボラーグ Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩
JP2015517469A (ja) 2012-05-01 2015-06-22 デユーク・ユニバーシテイ 移植片拒絶のバイオマーカーとしてのヘパラン硫酸の組成物および方法
JP2017522350A (ja) 2014-07-31 2017-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (online)，2016年，＜ＵＲＬ：https://clinicaltrials.gov/study/NCT02669251＞，［検索日：2024.08.07］
American Journal of Respiratory and Critical Care Medicine，1999年，Vol. 159, No. 1，pp. 258-261，＜URL: https://doi.org/10.1164/ajrccm.159.1.9712068＞
American Journal of Respiratory and Critical Care Medicine，2001年，Vol. 164, No. 1，pp. 97-102，＜URL: https://doi.org/10.1164/ajrccm.164.1.2006096＞
Transplant Infectious Disease，2001年，Vol. 3, No. 3，pp. 168-176，＜URL: https://doi.org/10.1034/j.1399-3062.2001.003003168.x＞
Transplantation，2010年，Vol. 90, No. 3，pp. 335-337，DOI: 10.1097/TP.0b013e3181e49bf2

Also Published As

Publication number Publication date
CA3154761A1 (en) 2021-03-25
CN114650819A (zh) 2022-06-21
JP2023500182A (ja) 2023-01-05
BR112022004861A2 (pt) 2022-06-07
IL290991A (en) 2022-05-01
WO2021053058A1 (en) 2021-03-25
AU2020349353A1 (en) 2022-04-14
KR20220079527A (ko) 2022-06-13
US20220354833A1 (en) 2022-11-10
EP4031138A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
JP7672641B2 (ja) 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
US20250276066A1 (en) Methods, compositions and compounds for treating age-related diseases and conditions
CN105073110B (zh) 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物
KR20180126497A (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
JP2010500283A (ja) チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
TWI794885B (zh) 全身紅斑性狼瘡之治療
KR20050033520A (ko) 면역염증 질환의 치료를 위한 조합
TW201909921A (zh) 治療組合
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
AU2021283886A1 (en) Dihomo-gamma linolenic acid (DGLA) is a novel senolytic
KR20220103750A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
US20250134870A1 (en) Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same
EP3376869B1 (en) Treatment of autoimmune disease
US20240382472A1 (en) Neutrophil elastase inhibitors for use in the treatment of fibrosis
JP2018528250A (ja) 移植片拒絶反応の処置方法
WO2021088975A1 (zh) 一种化合物用于预防或治疗移植物抗宿主病的用途
Sharma Chronic Graft-Versus-Host Disease
CN121001712A (zh) 用短链脂肪酸治疗皮肤病症
JP2023548475A (ja) Ｓ１ｐ１受容体に関係する病態を治療する方法
JP2025524621A (ja) Ｃｙｐ３ａ誘導剤及び／又はプロトンポンプ阻害剤と組み合わせてベルモスジルを投与する方法
HK40081737A (en) Etrasimod for use in the treatment of eosinophilic esophagitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250411

R150 Certificate of patent or registration of utility model

Ref document number: 7672641

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150